June 07, 2019

Janssen Biotech told a Virginia federal court that it's fine if several proposed classes want to combine their suits accusing the pharmaceutical company of delaying the entry of a generic version of its prostate cancer drug Zytiga, as long as the case gets moved to New Jersey.

The four “nearly identical” suits should definitely be combined, but only in the “proper district,” the drugmaker said in its Thursday filing.

Since the proposed classes, which include the city of Baltimore and Blue Cross Blue Shield of Louisiana, have accused Johnson & Johnson unit Janssen of launching sham patent litigation in New Jersey, the suit belongs there, the drugmaker said.

. . .

Baltimore is represented by Glasser & Glasser PLC, Cohen Milstein Sellers & Toll PLLC, Burns Charest LLP and city attorneys.

The complete article can be accessed here.